Marshall Wace, LLP Day One Biopharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 887,177 shares of DAWN stock, worth $5.86 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
887,177
Previous 1,097,762
19.18%
Holding current value
$5.86 Million
Previous $13.9 Million
49.42%
% of portfolio
0.01%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding DAWN
# of Institutions
196Shares Held
76.7MCall Options Held
138KPut Options Held
208K-
Atlas Venture Life Science Advisors, LLC6.43MShares$42.5 Million14.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$39.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$38 Million0.95% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$30 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.06MShares$26.8 Million0.14% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $486M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...